Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An ¹⁸F-FDG PET/CT Case Study

References

• Abdallah, C. G., H. M. De Feyter, L. A. Averill, L. Jiang, C. L. Averill, G. M. I. Chowdhury, P. Purohit, R. A. de Graaf, I. Esterlis, C. Juchem, et al. 2018. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 43 (10):2154–60. doi:10.1038/s41386-018-0136-3.
   PubMed Web of Science ®Google Scholar
• Barbey, A. K., R. Colom, and J. Grafman. 2013. Dorsolateral prefrontal contributions to human intelligence. Neuropsychologia 51 (7):1361–69. doi:10.1016/j.neuropsychologia.2012.05.017.
   PubMed Web of Science ®Google Scholar
• Boksa, P. 2009. On the neurobiology of hallucinations. Journal of Psychiatry & Neuroscience 34 (4):260–62.
   PubMed Web of Science ®Google Scholar
• Botanas, C. J., J. B. de la Peña, R. J. Custodio, I. J. Dela Peña, M. Kim, T. Woo, H. J. Kim, H. I. Kim, M. C. Cho, Y. S. Lee., et al. 2017. Methoxetamine produces rapid and sustained antidepressant effects probably via glutamatergic and serotonergic mechanisms. Neuropharmacology 126:121–27. doi:10.1016/j.neuropharm.2017.08.038.
   PubMed Web of Science ®Google Scholar
• Breier, A., A. K. Malhotra, D. A. Pinals, N. I. Weisenfeld, and D. Pickar. 1997. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. The American Journal of Psychiatry 154 (6):805–1. doi:10.1176/ajp.154.6.805.
   PubMed Web of Science ®Google Scholar
• Chiappini, S., H. Claridge, J. M. Corkery, C. Goodair, B. Loi, and F. Schifano. 2015. Methoxetamine-related deaths in the UK: An overview. Human Psychopharmacology: Clinical and Experimental 30 (4):244–48. doi:10.1002/hup.2422.
   PubMed Web of Science ®Google Scholar
• Corazza, O., F. Schifano, P. Simonato, S. Fergus, S. Assi, J. Stair, J. Corkery, G. Trincas, P. Deluca, Z. Davey, et al. 2012. Phenomenon of new drugs on the Internet: The case of ketamine derivative methoxetamine. Human Psychopharmacology: Clinical and Experimental 27 (2):145–49. doi:10.1002/hup.1242.
   PubMed Web of Science ®Google Scholar
• Corazza, O., S. Assi, and F. Schifano. 2013. From “Special K” to “Special M”: The evolution of the recreational use of ketamine and methoxetamine. CNS Neuroscience & Therapeutics 19 (6):454–60. doi:10.1111/cns.12063.
   PubMed Web of Science ®Google Scholar
• Ćurčić-Blake, B., L. Bais, A. Sibeijn-Kuiper, H. M. Pijnenborg, H. Knegtering, E. Liemburg, and A. Aleman. 2017. Glutamate in dorsolateral prefrontal cortex and auditory verbal hallucinations in patients with schizophrenia: A (1)H MRS study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 78:132–39. doi:10.1016/j.pnpbp.2017.05.020.
   PubMed Web of Science ®Google Scholar
• de Bartolomeis, A., C. Tomasetti, and F. Iasevoli. 2015. Update on the mechanism of action of aripiprazole: Translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs 29 (9):773–99. doi:10.1007/s40263-015-0278-3.
   PubMed Web of Science ®Google Scholar
• Deepmala, J. Slattery, N. Kumar, L. Delhey, M. Berk, O. Dean, C. Spielholz, and R. Frye. 2015. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neuroscience & Biobehavioral Reviews 55:294–321. doi:10.1016/j.neubiorev.2015.04.015.
   PubMed Web of Science ®Google Scholar
• Di Nicola, M., V. R. Ferri, L. Moccia, I. Panaccione, A. M. Strangio, D. Tedeschi, P. Grandinetti, A. Callea, F. De Giorgio, G. Martinotti, et al. 2017. Gender differences and psychopathological features associated with addictive behaviors in adolescents. Frontiers in Psychiatry 8 (1):256. doi:10.3389/fpsyt.2017.00256.
   PubMed Web of Science ®Google Scholar
• Fuster, J. 2015. The prefrontal cortex. 5th ed. London, UK: Academic Press.
   Google Scholar
• Kalivas, P. W. 2009. The glutamate homeostasis hypothesis of addiction. Nature Reviews Neuroscience 10 (8):561–72. doi:10.1038/nrn2515.
   PubMed Web of Science ®Google Scholar
• Kim, Y. T., S. W. Lee, D. H. Kwon, J. H. Seo, B. C. Ahn, and J. Lee. 2009. Dose-dependent frontal hypometabolism on FDG-PET in methamphetamine abusers. Journal of Psychiatric Research 43 (14):1166–70. doi:10.1016/j.jpsychires.2009.03.011.
   PubMed Web of Science ®Google Scholar
• Liao, Y., J. Tang, P. R. Corlett, X. Wang, M. Yang, H. Chen, T. Liu, X. Chen, W. Hao, and P. C. Fletcher. 2011. Reduced dorsal prefrontal gray matter after chronic ketamine use. Biological Psychiatry 69 (1):42–48. doi:10.1016/j.biopsych.2010.08.030.
   PubMed Web of Science ®Google Scholar
• Mathews, M. J., R. N. Mead, and M. Galizio. 2018. Effects of N-methyl-D-aspartate (NMDA) antagonists ketamine, methoxetamine, and phencyclidine on the odor span test of working memory in rats. Experimental and Clinical Psychopharmacology 26 (1):6–17. doi:10.1037/pha0000158.
   PubMed Web of Science ®Google Scholar
• Moccia, L., M. Mazza, M. Di Nicola, and L. Janiri. 2018. The experience of pleasure: A perspective between neuroscience and psychoanalysis. Frontiers in Human Neuroscience 4 (12):359. doi:10.3389/fnhum.2018.00359.
   Web of Science ®Google Scholar
• Moccia, L., M. Pettorruso, F. De Crescenzo, L. De Risio, L. Di Nuzzo, G. Martinotti, A. Bifone, L. Janiri, and M. Di Nicola. 2017. Neural correlates of cognitive control in gambling disorder: A systematic review of fMRI studies. Neuroscience & Biobehavioral Reviews 78:104–16. doi:10.1016/j.neubiorev.2017.04.025.
   PubMed Web of Science ®Google Scholar
• Moghaddam, B., and D. Javitt. 2012. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37 (1):4–15. doi:10.1038/npp.2011.181.
   PubMed Web of Science ®Google Scholar
• Moreno-López, L., E. A. Stamatakis, M. J. Fernández-Serrano, M. Gómez-Río, A. Rodríguez-Fernández, M. Pérez-García, and A. Verdejo-García. 2012. Neural correlates of the severity of cocaine, heroin, alcohol, MDMA and cannabis use in polysubstance abusers: A resting-PET brain metabolism study. PloS one 7 (6):e39830. doi:10.1371/journal.pone.0039830.
   PubMed Web of Science ®Google Scholar
• Neill, J. C., S. Barnes, S. Cook, B. Grayson, N. F. Idris, S. L. McLean, S. Snigdha, L. Rajagopal, and M. K. Harte. 2010. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism. Pharmacology & Therapeutics 128 (3):419–32. doi:10.1016/j.pharmthera.2010.07.004.
   PubMed Web of Science ®Google Scholar
• Passingham, R. E., and S. P. Wise. 2012. The neurobiology of the prefrontal cortex: Anatomy, evolution, and the origin of thought. Oxford: Oxford University Press.
   Google Scholar
• Potkin, S. G., G. Alva, K. Fleming, R. Anand, D. Keator, D. Carreon, M. Doo, Y. Jin, J. C. Wu, and J. H. Fallon. 2002. A PET study of the pathophysiology of negative symptoms in schizophrenia. The American Journal of Psychiatry 159 (2):227–37. doi:10.1176/appi.ajp.159.2.227.
   PubMed Web of Science ®Google Scholar
• Seeley, W. W., V. Menon, A. F. Schatzberg, J. Keller, G. H. Glover, H. Kenna, A. L. Reiss, and M. D. Greicius. 2007. Dissociable intrinsic connectivity networks for salience processing and executive control. Journal of Neuroscience 27 (9):2349–56. doi:10.1523/JNEUROSCI.5587-06.2007.
   PubMed Web of Science ®Google Scholar
• Terbeck, S., F. Akkus, L. P. Chesterman, and G. Hasler. 2015. The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: Combining preclinical evidence with human Positron emission tomography (PET) studies. Frontiers in Neuroscience 9:86. doi:10.3389/fnins.2015.00086.
   PubMed Web of Science ®Google Scholar
• Tracy, D. K., D. M. Wood, and D. Baumeister. 2017. Novel psychoactive substances: Types, mechanisms of action, and effects. BMJ 25:i6848. doi:10.1136/bmj.i6848.
   Web of Science ®Google Scholar
• Varrone, A., S. Asenbaum, T. Vander Borght, J. Booij, F. Nobili, K. Någren, J. Darcourt, O. L. Kapucu, K. Tatsch, P. Bartenstein, et al.; European Association of Nuclear Medicine Neuroimaging Committee. 2009. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. European Journal of Nuclear Medicine and Molecular Imaging. 36 (12):2103–10. doi:10.1007/s00259009-1264-0.
   PubMed Web of Science ®Google Scholar
• Vollenweider, F. X., and M. A. Geyer. 2001. A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Research Bulletin 56 (5):495–507. doi:10.1016/S0361-9230(01)00646-3.
   PubMed Web of Science ®Google Scholar
• Wang, M., and A. F. Arnsten. 2015. Contribution of NMDA receptors to dorsolateral prefrontal cortical networks in primates. Neuroscience Bulletin 31 (2):191–97. doi:10.1007/s12264-014-1504-6.
   PubMed Web of Science ®Google Scholar
• WHO (2015). Methoxetamine (MXE) critical review report 37th ECDD agenda item 5.9. http://www.who.int/medicines/access/controlled-substances/5.9_Methoxetamine_CRev.pdf.
   Google Scholar
• Zanda, M. T., P. Fadda, C. Chiamulera, W. Fratta, and L. Fattore. 2016. Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects. Behavioural Pharmacology 27 (6):489–96. doi:10.1097/FBP.0000000000000241.
   PubMed Web of Science ®Google Scholar
• Zanda, M. T., P. Fadda, S. Antinori, M. Di Chio, W. Fratta, C. Chiamulera, and L. Fattore. 2017. Methoxetamine affects brain processing involved in emotional response in rats. British Journal of Pharmacology 174 (19):3333–45. Portico. doi:10.1111/bph.13952.
   PubMed Web of Science ®Google Scholar